Stock Ratings / Health Care / PRLD / options

ENTA (20) ARCT (25) IRD (23) BNTC (30) ⌘ Pro Terminal →

Prelude Therapeutics Incorporated (PRLD) Options Positioning, Max Pain & Unusual Sweeps

$3.88 -5.37% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.84

Prelude Therapeutics Incorporated (PRLD) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $309.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PRLD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PRLD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Prelude Therapeutics Incorporated (NASDAQ: PRLD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $3.88 (-5.37% 1D, market cap $309.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PRLD ranks #680 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PRLD compare to ENTA and ARCT in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRLD carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ENTA (Enanta Pharmaceuticals Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $311.9M) and ARCT (Arcturus Therapeutics Holdings Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $313.5M). Among the 5-stock peer group, PRLD leads on earnings multiple (N/A) while PRLD leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PRLD?

▼

Per PRLD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001678660), Prelude Therapeutics Incorporated generated $12.1M in revenue (+73.4% YoY), -$99.5M in net income, and -$56.4M in free cash flow against $141.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.83 (-1.16%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRLD)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (33/100 Composite)

🔍 WHY PRLD SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.56-0.8% Next Q

Q2 (-2Q)

Grade E$3.53+9.9% Next Q

Q3 (-1Q)

Grade E$3.88+0% Next Q

Current

Grade E$3.88-8.9% Hist 90D α

Trajectory: E (25) → E (33)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PRLD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PRLD currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.35) and Max Pain ($4.07) forces dealer call-delta covering toward $7.17.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRLD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PRLD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 33%NO 67%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (PRLD)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for PRLD.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRLD)

✓Walkthrough of PRLD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PRLD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.14%📐 HORIZONTAL RANGE

2026-11-03O $4.10H $4.10L $3.88C $3.88VOL 218.1K

RES: $7.86SUP: $3.06SMA50: $4.35SMA200: $4.03

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRLD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRLD Butterfly Map → + Track PRLD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +73.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PRLD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRLD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PRLD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRLD)

Health Care Rank #680 of 1016 ⚔️ ENTA vs PRLD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRLD vs. ENTA, ARCT, IRD, BNTC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Prelude Therapeutics Incorporated (PRLD) ranks #680 by composite RQD confidence (33/100, grade E) and #512 by equity capitalization ($309.6M). Within this direct 5-issuer industry benchmark cohort, PRLD leads on earnings valuation at N/A trailing P/E, while PRLD leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PRLD currently leads its immediate peer cohort in composite quantitative strength at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PRLD ACTIVE Prelude Therapeutics Incorporated	E	33/100	—	—	-35.0%	-5.37%	$309.6M	Benchmark Subject
ENTA Enanta Pharmaceuticals Inc.	E	20/100	—	—	-35.0%	-3.95%	$311.9M	/enta-vs-prld →
ARCT Arcturus Therapeutics Holdings Inc.	E	25/100	—	—	-35.0%	-9.22%	$313.5M	/arct-vs-prld →
IRD Opus Genetics Inc.	E	23/100	—	—	-35.0%	+0.55%	$305.3M	/ird-vs-prld →
BNTC Benitec Biopharma Inc.	E	30/100	—	—	-35.0%	-1.02%	$304.9M	/bntc-vs-prld →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001678660

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Prelude Therapeutics Incorporated (PRLD) reported GAAP revenue of $12.1M (+73.4% vs. FY2024 revenue of $7.0M ) , GAAP net income of -$99.5M, operating cash flow of -$56.3M, and free cash flow of -$56.4M (+45.6% YoY). On the balance sheet, PRLD closed FY2025 with $141.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$12.1M	-$99.5M	-$56.3M	-$56.4M	$141.3M	—
FY2024 (FY)	2024-12-31	$7.0M	-$127.2M	-$102.9M	-$103.7M	$175.5M	—
FY2023 (FY)	2023-12-31	$0	-$121.8M	-$107.1M	-$107.1M	—	—

3. PRLD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRLD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PRLD compare to ENTA and ARCT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PRLD?

Where is PRLD trading relative to its 50-day, 200-day, and 52-week technical levels?

PRLD last traded at $3.88 (-5.37% on volume of 218,111 shares), positioning the stock -10.80% below its 50-day simple moving average ($4.35) and -3.72% below its 200-day simple moving average ($4.03). Across its 52-week range of $1.17 to $6.83, PRLD sits at the 47.9% percentile with a 14-day RSI of 48.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.40 to $4.36).

PRLD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is PRLD's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for PRLD.

Direct Sub-Reports: PRLD RQD Cockpit PRLD 12M Forecast PRLD Earnings & Move PRLD Dividends & DRIP PRLD Insiders & 13F PRLD Whale Options PRLD Profit Sankey PRLD News & Why

ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PRLD — Prelude Therapeutics Incorporated: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:38:23Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PRLD scores 41 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars: the Fundamental Cash Engine scores 8/20 (ROIC of -35%; FCF yield of -17.23%), indicating the business is not currently generating cash returns on capital. Whale 13F Flow scores 10/20, reflecting institutional accumulation and options positioning that is present but not strong enough to lift the rating. Insider Conviction scores 3/20 on the basis of SEC Form 4 and Congressional PTR cluster flow, the weakest pillar in the rating. Macro Regime Fit scores 9/20 with a beta of 1.0 and sector sensitivity noted. Forensic Balance Sheet scores 11/20, drawing on an Altman Z of 2.5, a Piotroski F of 4/9, and a Debt/Equity of 0.5.

For a prospective investor, the upside case rests on the business reaching a point where operating losses narrow; the source data does not show that yet. Valuation cannot be anchored to earnings because P/E and EPS are not available in source data, so any assessment must lean on balance sheet resilience and cash burn trajectory. The rating signals that the balance sheet and cash flow profile are the primary risk factors. This is an educational summary of the rating's components, not personalized advice.

Business

Prelude Therapeutics Incorporated (PRLD) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, its market capitalization is $0.3B. The source data does not describe the specific products sold, the customer base, or the detailed revenue model. Reported revenue of $12.1M for FY 2025 is shown in the SEC financials, but its composition is not detailed in source data.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$12.1M	$-104.6M	$-99.5M	N/A	$-56.4M	$35.3M	N/A
FY 2024	$7.0M	$-139.7M	$-127.2M	N/A	$-103.7M	$12.5M	N/A
FY 2023	$0.0M	$-132.3M	$-121.8M	N/A	$-107.1M	N/A	N/A

Per the SEC financials, the company reported operating losses across all three periods, with FY 2025 operating income of $-104.6M narrowing from $-139.7M in FY 2024. Operating margin is -60% and net margin is -60% per market data, with gross margin at 0%. ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 4/9, and Debt/Equity is 0.5. Cash rose to $35.3M in FY 2025 from $12.5M in FY 2024, but free cash flow remained negative at $-56.4M.

Recent Catalysts & News Wire Analysis

Per the recent news feed, several headlines reference a potential $100M Incyte option tied to the JAK2 and KAT6A programs, and a Lilly deal with a Citizens price target of USD 6.00. A TradingView item cites a Q3'26 revenue estimate of 29.00M USD. Several items are flagged YELLOW (market wire) and one GREEN (catalyst, related to a healthcare sector earnings preview). These headlines are referenced by title only; the source data does not confirm deal terms beyond these headlines. Risk watch items include the sustained operating losses and negative free cash flow noted above. Per the Butterfly Supply-Chain Graph, no proprietary signals or supply-chain links are recorded.

Open Questions

What are the specific terms and status of the referenced Incyte option and Lilly arrangement, and do they convert to recognized revenue?
What is the company's cash runway given FY 2025 free cash flow of $-56.4M against $35.3M in cash?
What is the composition and debt structure behind the reported Debt/Equity of 0.5, given debt is listed as N/A in the financials?
Why are EPS and forward earnings unavailable, and when does the company expect to reach operating breakeven?

PRLD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Prelude Therapeutics Incorporated (PRLD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PRLD Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 18h ago

Prelude Therapeutics Incorporated (PRLD) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 21h ago

Prelude Therapeutics Incorporated Estimates – NASDAQ:PRLD

TradingView report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option

Yahoo Finance report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 1d ago

Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?

TradingView report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Prelude Therapeutics secures Lilly deal. Citizens targets Prelude Therapeutics stock at USD 6.00

ad-hoc-news.de report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

PRLD Q3'26 Earnings: revenue estimate is 29.00M USD

TradingView report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Pulmonx Corporation (LUNG) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Prelude Therapeutics stock outlines three-program clinical strategy

ad-hoc-news.de report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PRLD Bull vs. Bear Conversation Board — What's Your Call at $3.88?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PRLD 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $3.61 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PRLD (D- • RQD 41/100) a Buy at $4.10?

Welcome to the PRLD (Prelude Therapeutics Incorporated) Roar Pit. Current RQD Composite is 41/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $3.24 (-21.0%)

Spot @ $4.10

Pump the brakes on PRLD — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PRLD, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Prelude Therapeutics Incorporated expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $4.88 (+19.0%)

Spot @ $4.10

PRLD cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PRLD, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $4.10 (52-wk range $1.17 - $6.83), any beat on forward guidance forces shorts and underweight funds to chase.